FDA designates Scynexis antibiotic SCY-078 'qualified infectious disease' product
This article was originally published in Scrip
The FDA has designated Scynexis' investigational antibiotic SCY-078, previously known as MK-3118, a qualified infectious disease product (QIDP) – a status that could garner the experimental medicine an additional five years of market exclusivity if approved for oral use for the indications of invasive Candidiasis, including Candidemia and invasive Aspergillosis.
You may also be interested in...
Scrip spoke with several executives and attended multiple panel discussions in San Francisco during the first full day of BIO's annual international gathering. Drug pricing and enabling innovation emerged as key themes.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.